Paul
03-29-2004, 05:28 AM
NeoPharm Inc. (Nasdaq/NM:NEOL) announced today that data for its new technology for entrapping two drugs in a single liposome for combination therapy was presented via poster presentation on Sunday March 28th at the 2004 American Association for Cancer Research (AACR) in Orlando Florida. The Company refers to its new technology as "Tandem Technology."
Liposomes are microscopic membrane-like structures created from lipids (fats). Because tumor cells need to consume large amounts of fats to sustain their extremely rapid growth they recognize the liposomal drug as a potential source of nutrition and consume it along with the chemotherapeutic drugs. Accordingly the liposome produces a "Trojan Horse" effect in attacking the cancer cell.
By incorporating drugs into liposomes the toxicity of the drug may be reduced (patients may experience fewer side effects) therapeutic efficacy or potency of the drug is maintained and in some cases more of the drug can be administered and reach the tumor resulting in a better therapeutic effect.
NeoPharm's preliminary studies of the paclitaxel/doxorubicin lipsomal drug formulation on tumor-bearing mice showed promising results in overcoming resistant cancers.
Liposomes are microscopic membrane-like structures created from lipids (fats). Because tumor cells need to consume large amounts of fats to sustain their extremely rapid growth they recognize the liposomal drug as a potential source of nutrition and consume it along with the chemotherapeutic drugs. Accordingly the liposome produces a "Trojan Horse" effect in attacking the cancer cell.
By incorporating drugs into liposomes the toxicity of the drug may be reduced (patients may experience fewer side effects) therapeutic efficacy or potency of the drug is maintained and in some cases more of the drug can be administered and reach the tumor resulting in a better therapeutic effect.
NeoPharm's preliminary studies of the paclitaxel/doxorubicin lipsomal drug formulation on tumor-bearing mice showed promising results in overcoming resistant cancers.